Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Work In Process (2023 - 2025)

Historic Work In Process for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q1 2025 value amounting to $12.1 million.

  • Iovance Biotherapeutics' Work In Process rose 10439.63% to $12.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.1 million, marking a year-over-year increase of 10439.63%. This contributed to the annual value of $8.8 million for FY2024, which is 5246.13% up from last year.
  • As of Q1 2025, Iovance Biotherapeutics' Work In Process stood at $12.1 million, which was up 10439.63% from $8.8 million recorded in Q4 2024.
  • Over the past 5 years, Iovance Biotherapeutics' Work In Process peaked at $12.1 million during Q1 2025, and registered a low of $4.3 million during Q3 2023.
  • Its 3-year average for Work In Process is $7.6 million, with a median of $7.3 million in 2023.
  • Its Work In Process has fluctuated over the past 5 years, first soared by 5246.13% in 2024, then surged by 10439.63% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Work In Process stood at $5.7 million in 2023, then surged by 52.46% to $8.8 million in 2024, then skyrocketed by 37.91% to $12.1 million in 2025.
  • Its last three reported values are $12.1 million in Q1 2025, $8.8 million for Q4 2024, and $5.9 million during Q1 2024.